Clomifene - Veru Healthcare

Drug Profile

Clomifene - Veru Healthcare

Alternative Names: Cis and trans clomifene - Veru Healthcare; Clomiphene - Veru Healthcare; MSS 722; VERU 722

Latest Information Update: 27 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aspen Park Pharmaceuticals
  • Developer Veru Healthcare
  • Class
  • Mechanism of Action Estrogen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypogonadism; Male infertility

Most Recent Events

  • 27 Jun 2017 Preclinical trials in Male infertility in USA (PO) before June 2017 before June 2017 (Veru Healthcare website, June 2017)
  • 27 Jun 2017 Veru Helathcare announces intention to submit an IND application to US FDA for Hypogonadism and male infertility in 2017 (Veru Healthcare website, June 2017)
  • 27 Jun 2017 Veru Healthcare plans a phase II trial for Hypogonadism and male infertility in USA in 2017 (Veru Healthcare pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top